文献速递乳腺MR

三阴性乳腺癌患者新辅助化疗联合卡瑞利珠单抗免疫治疗期间MRI上乳腺内良性血管增殖性病变

Intramammary benign vascular proliferative lesions on MRI during neoadjuvant chemoimmunotherapy with camrelizumab in TNBC patients.
PubMed 文献 · Eur J Radiol · 2025-11-22

回顾性单中心分析106例三阴性乳腺癌患者(2021年3月至2023年8月),其中60例接受新辅助化疗、46例接受卡瑞利珠单抗联合新辅助化疗免疫治疗。MRI显示异常强化在NACI组27例、NAC组3例(P<0.001),NACI组以肿块样强化为主(22/27,81.5%),多出现在第2周期后,26/27(96.3%)继续治疗后消退。

要点

  • 卡瑞利珠单抗联合新辅助化疗的三阴性乳腺癌患者中,乳腺内可出现良性血管增殖性病变,MRI多表现为肿块样强化。
  • 此类异常强化多在第2治疗周期后出现,少数在第4或第6周期后出现;多数(26/27,96.3%)继续治疗后自行消退。
  • 新发强化病变与年轻年龄(P=0.007)、绝经前状态(P=0.014)、基线MRI无瘤周水肿(P=0.007)及肿块样强化(P=0.012)相关。

核心结论

  • 接受卡瑞利珠单抗治疗的三阴性乳腺癌患者乳腺组织内常出现良性血管增殖性病变,MRI上主要表现为肿块样强化,通常继续治疗后可消退,无需中断治疗。

研究设计与样本

  • 回顾性单中心分析,纳入2021年3月至2023年8月间106例三阴性乳腺癌患者(平均年龄48.1±11.2岁),其中60例接受新辅助化疗、46例接受卡瑞利珠单抗联合新辅助化疗免疫治疗,分析基线及每个治疗周期的临床、病理及MRI资料。

关键影像表现/征象

  • NACI组异常强化表现为环形强化3例(3/27,11.1%)、线样强化2例(2/27,7.4%)、肿块样强化22例(22/27,81.5%);异常强化在NACI组27例 vs NAC组3例(P<0.001)。

局限性

  • 原文为回顾性单中心分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a common immune-related adverse event (irAE) associated with camrelizumab. We aimed to explore and describe benign vascular proliferative lesions occurring within breast tissue of triple-negative breast cancer (TNBC) patients undergoing neoadjuvant chemoimmunotherapy (NACI) with camrelizumab.

METHODS: We conducted a retrospective single-center analysis of 106 TNBC patients treated between March 2021 and August 2023 (mean age 48.1 ± 11.2 years). The cohort included 60 patients receiving neoadjuvant chemotherapy (NAC) and 46 patients who underwent NACI with camrelizumab. Clinical data, pathological characteristics, and MRI findings at baseline and during each treatment cycle were analyzed for all participants. Post-treatment newly identified abnormal lesions within breast tissue were detected and characterized.

RESULTS: Abnormal enhancement was observed in 30 patients (3 NAC vs. 27 NACI, P < 0.001). In the NACI group, abnormal enhancement included 3 cases of ring enhancement (3/27, 11.1 %), 2 cases of linear enhancement (2/27, 7.4 %), and 22 cases of mass enhancement (22/27, 81.5 %). These lesions typically emerged after the second treatment cycle, with few appearing after the fourth or sixth cycle. Most lesions (26/27, 96.3 %) regressed with continued treatment. In the NACI group, the development of new enhancement lesions was correlated with younger age (P = 0.007), premenopausal status (P = 0.014), a lack of peritumoral edema on baseline MRI (P = 0.007), and the presence of mass enhancements (P = 0.012).

CONCLUSION: TNBC patients treated with camrelizumab frequently develop benign vascular proliferative lesions in the breast tissue, primarily manifesting as mass enhancements on MRI that typically regress with continued treatment without requiring therapy discontinuation.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ma X, Wang Y, Hu F, et al. Intramammary benign vascular proliferative lesions on MRI during neoadjuvant chemoimmunotherapy with camrelizumab in TNBC patients. Eur J Radiol. 2025. PMID: 41308572. doi:10.1016/j.ejrad.2025.112568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。